Revelation Biosciences Inc (REVB) USD0.001

Sell:$3.00Buy:$3.32$0.02 (0.66%)

Prices delayed by at least 15 minutes
Sell:$3.00
Buy:$3.32
Change:$0.02 (0.66%)
Prices delayed by at least 15 minutes
Sell:$3.00
Buy:$3.32
Change:$0.02 (0.66%)
Prices delayed by at least 15 minutes

Company Information

About this company

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.

Key people

James M. Rolke
Chief Executive Officer, Co-Founder, Director
Chester S. Zygmont
Chief Financial Officer
George F. Tidmarsh
Independent Chairman of the Board
Jennifer A. Carver
Independent Director
Lakhmir S. Chawla
Independent Director
Jess Roper
Independent Director
Click to see more

Key facts

  • EPIC
    REVB
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US76135L6065
  • Market cap
    $3.02m
  • Employees
    8
  • Shares in issue
    963,796.00
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.